Restaurants Dodge New Food Tracking Paperwork—for Now
Published Date: 10/9/2026
Proposed Rule
Summary
The FDA is sharing a draft plan about new food tracking rules that mostly won’t apply to certain stores and restaurants right now. If you run a retail food place or restaurant, you don’t have to worry about extra paperwork just yet, but the FDA wants your feedback by November 23, 2026. This helps them decide the final rules without causing extra costs or hassle for small businesses.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Existing full exemption for very small retailers
If your retail food store or restaurant has an average annual monetary value of food sold or provided of $250,000 or less (calculated on a rolling 3-year basis and adjusted for inflation using 2020 as the baseline), you are fully exempt from the Food Traceability Rule. That means FDA’s rule does not apply to your business under that threshold.
Enforcement discretion for mid-size retailers and restaurants
For retail food establishments and restaurants with an average annual monetary value of food sold or provided greater than $250,000 but no more than $1,000,000 (on a rolling 3-year basis, adjusted for inflation using 2020 as the baseline), FDA currently intends not to enforce the Food Traceability Rule's requirements. This gives those businesses temporary relief from enforcement of the traceability requirements while the agency considers feedback.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-20701, Airworthiness Directives; Airbus SAS Airplanes
The FAA wants all Airbus A350-941 and -1041 planes checked because a safety hook got stuck due to too much sealant. They’re asking for detailed inspections and fixes to keep everyone safe. Comments are open until November 23, 2026, so airlines should act fast to avoid any costly delays or risks.
Next: 2026-20735, Extensions of Credit to Insiders
The FDIC is giving banks and insiders more time to share their thoughts on new rules about loans to insiders by extending the comment deadline to November 4, 2026. These rules aim to keep lending fair and safe, especially when insiders like executives or board members borrow money. If you’re involved with banks or interested in fair lending, now’s your chance to speak up before the final rules are set!